Saudi Vision 2030 and NUPCO 2026 Localisation Rules: What UK Pharmaceutical Exporters Need to Know

Saudi Arabia has spent the better part of a decade rewriting how it buys medicines. Vision 2030, the long-running national transformation strategy, set healthcare as one of the central pillars of the diversification programme, and the National Unified Procurement Company, known to most of the industry simply as NUPCO, was created to consolidate purchasing across Ministry of Health hospitals, military medical services, and National Guard medical services into a single, professionally run buyer. Through 2024 and 2025 the framework was largely about scale and efficiency. From 2026, the framework has shifted decisively toward localisation.

The 2026 NUPCO procurement rules, as understood from public regulatory updates and tender documentation circulated in early 2026, prioritise pharmaceutical products that are both registered with the Saudi Food and Drug Authority and manufactured locally inside the Kingdom. For routine therapy categories where Saudi local manufacturing capacity now exists, the practical effect is that imported finished products from outside the Kingdom face significantly tightened access to NUPCO tender awards. For the United Kingdom export community, this is a genuine inflection point and one that demands a clear-eyed strategic response rather than a reactive one.

The strategic response, however, is not retreat. It is precision. The 2026 rules carry exemptions, and those exemptions cover precisely the segments where UK MHRA-licensed wholesalers have always been most relevant: named patient supply for individual identified patients, urgent shortage supply when local manufacture fails or stocks out, and specialty supply for therapeutic categories where no SFDA-approved local manufacture exists. These are the segments that Vision 2030 cannot localise because, by definition, no local equivalent is available. They are the segments that hospitals, particularly the country's flagship tertiary centres, will continue to source from the United Kingdom and the wider international market for the foreseeable future.

This guide explains, in detail, what Vision 2030 set out to achieve, how NUPCO actually procures medicines, what the 2026 localisation rule changes cover and what they exempt, which Saudi hospital chains continue to need international supply, and how a UK MHRA-licensed wholesaler such as Euro Biom approaches the post-2026 landscape. It is written for procurement teams, hospital pharmacy leads, regulatory affairs professionals at UK manufacturers, and the local agents in Riyadh and Jeddah who connect international supply to Saudi clinical demand. The goal is not to alarm. It is to clarify exactly where UK suppliers remain essential and where they do not.

Why This Matters Now: The 2026 Inflection Point

For the better part of two decades, the Saudi pharmaceutical market has been one of the largest in the Middle East and a consistent destination for international supply. Hospital pharmacy formularies in Riyadh, Jeddah, Dammam, and the Eastern Province routinely included substantial volumes of imported finished products, sourced through licensed local agents and tendered through hospital-level or, latterly, NUPCO-led procurement. UK MHRA-licensed wholesalers have been, and remain, an important part of that international supply story.

What changes in 2026 is not the existence of import access. Saudi Arabia has neither the manufacturing capacity nor the regulatory mandate to localise every therapeutic area, and no serious policy maker has suggested otherwise. What changes is the default. Where previous tender frameworks treated locally manufactured and imported finished products as broadly comparable on price and quality, the 2026 rules introduce a clearer preference for SFDA-approved locally manufactured products in routine therapy categories, with exempt pathways defined for the cases where local manufacture is not available, not adequate, or not appropriate.

That shift in default has practical consequences. UK suppliers who were positioned for routine commodity supply, common cardiovascular generics, broad-spectrum antibiotics, standard analgesics, and other categories with established Saudi local manufacture, will find tender access in those segments much harder. UK suppliers who are positioned for the specialty, named patient, and shortage segments will find their value proposition sharpened rather than diminished. The 2026 rules effectively reward UK exporters who understand exactly where the exemptions sit and who can support hospital pharmacy teams within those exempt pathways with documentation, regulatory diligence, and supply reliability.

This guide is written for UK exporters who want to be in the second category.

Vision 2030: The Broader Healthcare Ambition

Vision 2030 was launched in April 2016 as the long-term framework for Saudi Arabia's economic and social diversification away from its traditional oil-revenue dependency. The programme is structured around three thematic pillars: a vibrant society, a thriving economy, and an ambitious nation. Healthcare sits across all three. Universal access to high-quality care is part of the social pillar, the development of a Saudi-based healthcare manufacturing and biotechnology industry is part of the economic pillar, and the transformation of the public health system into a more accountable, performance-driven structure is part of the ambitious nation pillar.

Three operational programmes give Vision 2030 healthcare ambitions concrete form. The Health Sector Transformation Programme is the umbrella for the structural reforms that include the corporatisation of public hospital networks, the introduction of accountable care organisations, and the separation of payer, provider, and regulator functions inside the Ministry of Health. The National Industrial Development and Logistics Programme covers the build-out of Saudi-based manufacturing across multiple sectors, with a substantial pharmaceutical and medical device chapter. The Privatisation Programme covers the selective transfer of public sector services to private operators, including significant components of healthcare delivery.

From a UK exporter's vantage point, the most consequential of these is the National Industrial Development and Logistics Programme. It explicitly targets the localisation of pharmaceutical manufacturing, with public commitments to raise the share of locally manufactured medicines in public sector procurement and to attract international manufacturers to set up Saudi-based production. By 2026, that aspiration has translated into both concrete manufacturing capacity, with active SPIMACO, Tabuk Pharmaceuticals, Jamjoom Pharma, SAJA, and Riyadh Pharma facilities, and increased multinational presence through GlaxoSmithKline Saudi Arabia, Boehringer Ingelheim Saudi Arabia, and others, and into procurement policy that aligns NUPCO purchasing with the localisation goal.

It is important to read Vision 2030 honestly. It is not a closed-borders policy. It is an industrial policy, with healthcare as one of its central planks. The ambition is to reduce import dependency in categories where local manufacture is feasible, not to eliminate imports altogether. UK exporters who interpret it as the latter will misread the opportunity. UK exporters who interpret it as a structural shift toward localisation in routine categories, with continuing demand for international supply in exempt categories, will read it correctly.

NUPCO's Role: How Saudi Public Hospitals Actually Buy

The National Unified Procurement Company was established in 2009 as a joint stock company owned by the Public Investment Fund. Its mandate is to act as the single buyer for medicines and medical supplies on behalf of the public sector. In practice, that means three principal buyers funnel demand through NUPCO: the Ministry of Health, which operates the country's main public hospital network and primary care system; the Ministry of Defence Health Services, which runs military hospitals; and the Ministry of National Guard Health Affairs, which operates the National Guard medical service. The Royal Medical Services and certain other specialised entities also use NUPCO for portions of their procurement.

NUPCO operates an electronic tendering platform through which suppliers, working in coordination with their authorised local agents, respond to framework tenders, mini-tenders, and specific product calls. Suppliers who succeed in tender award are placed on framework agreements that specify product, price, lead time, and minimum quality standards. Hospital pharmacy directors and procurement officers within the participating ministries then call off against these framework agreements when ordering for their facilities. The model concentrates purchasing power, simplifies vendor management, drives volume discounts, and gives the Kingdom much greater leverage in negotiations with international manufacturers.

Crucially, NUPCO does not procure for the entirety of Saudi healthcare demand. Private hospitals, private clinics, and private pharmacy chains operate outside the NUPCO framework and source medicines through their own commercial arrangements with licensed local agents. King Faisal Specialist Hospital and Research Centre, while a public institution, has historically maintained substantial autonomy in its specialty procurement, particularly for oncology, cardiology, and rare disease products. Some Ministry of Health hospitals retain limited local procurement authority for urgent or specialty cases that fall outside the NUPCO framework. The Special Access Program, which is the named patient pathway, operates as a parallel channel administered through SFDA and hospital ethics committees rather than through NUPCO tendering.

For UK exporters, this distinction is fundamental. The 2026 localisation rules apply to NUPCO framework procurement of routine therapy categories. They do not, and cannot, apply to the channels that exist outside NUPCO: specialty procurement at the major tertiary centres, named patient supply, urgent shortage fills, and private sector demand. UK suppliers who understand which channel a particular order should flow through will find their value proposition intact.

The 2026 Localisation Rule Explained

The headline of the 2026 rule, distilled to its working form, is this: in routine therapy categories where SFDA-approved locally manufactured products exist, NUPCO framework tenders preference those locally manufactured products over imported finished products. The rule is implemented through a combination of tender eligibility criteria, scoring weightings that favour local content, and in some product categories, restrictions on the inclusion of imported finished products in the bid set at all.

The mechanics, as understood from 2026 regulatory updates and circulated tender documentation, work along the following dimensions:

• SFDA marketing authorisation remains a gating requirement. No product enters NUPCO procurement without an SFDA registration appropriate to its category. This has not changed.
• Local content classification has become explicit. Products are classified by the proportion of manufacturing that takes place inside the Kingdom: fully locally manufactured, locally finished from imported active ingredients, or fully imported finished product. The classification carries direct procurement weight.
• In categories with viable local manufacture, fully imported finished products may be excluded from routine framework tenders. The category-by-category determination rests with NUPCO and the relevant ministerial buyers and is updated periodically.
• Exempt categories preserve international access. Products with no SFDA-approved locally manufactured equivalent, urgently needed shortage fills, named patient and special access cases, and certain specialty product classes remain accessible through international supply.
• Documentation and quality requirements have not relaxed. Imported product entering through exempt channels still requires full GDP-compliant documentation, including Certificate of Pharmaceutical Product, batch documentation, certificate of analysis, and where applicable, cold chain validation records.

The interpretation that matters for UK exporters is this. The 2026 rule does not close the Saudi market. It segments it. Routine therapy categories with established local manufacture are increasingly closed to imported finished products through routine NUPCO tendering. Specialty, named patient, shortage, and exempt categories remain fully accessible. The strategic question for any UK exporter is not whether to continue serving Saudi Arabia, but which segments to focus on.

The Three Exempt Segments Where UK Exporters Still Play

Three exempt segments anchor the post-2026 UK supply story to Saudi Arabia. Each operates under a different regulatory mechanism, each carries different documentation requirements, and each serves a different clinical need. UK exporters who understand the distinctions between them will be far better placed than those who treat them as a single undifferentiated channel.

1. Named Patient Supply

Named patient supply, administered in Saudi Arabia through the Special Access Program at the SFDA, allows licensed importation of an unregistered or non-locally-available medicine for a specific identified patient. The Saudi mechanism mirrors the principle behind UK named patient supply under Regulation 167 of the Human Medicines Regulations 2012, although the local administrative process is different. A clinician at a Saudi hospital identifies a clinical need that cannot be met by any locally available product. The hospital's pharmacy and therapeutics committee or equivalent body reviews the case. A Special Use or Special Access application is submitted to the SFDA with the clinical justification, the proposed product details, and the identified supplier. Once approved, a shipment-specific import permit is issued and the product is imported through a licensed local agent.

The named patient pathway is, by design, untouchable by localisation policy. The whole rationale of the pathway is that the patient cannot be served by any locally available product. UK MHRA-licensed wholesalers continue to play the central role in fulfilling these requests, particularly for oncology orphan agents, advanced biologics, rare disease enzyme replacements, and other products where the global manufacturing footprint is concentrated in the United Kingdom, Western Europe, or the United States.

2. Shortage Supply

Shortage supply covers the urgent procurement of a medicine when the locally manufactured or routinely supplied source has failed: a manufacturing line interruption, a quality recall, a sudden demand spike, an unforeseen supply chain disruption. NUPCO and the SFDA both maintain mechanisms to source urgent stock-out fills from international suppliers, on the understanding that patient care must be continued and that the locally manufactured channel cannot, in the short term, meet demand. Shortage supply is typically time-bound, quantity-limited, and clearly framed as a bridging measure rather than a structural channel. The 2026 localisation rules explicitly preserve shortage supply as an exempt pathway because the policy aim is patient care continuity, not import substitution at the cost of clinical disruption.

UK exporters with depth, fast documentation turnaround, GDP-compliant cold chain capability, and same-day Heathrow dispatch are particularly well placed to support shortage supply. Saudi hospital pharmacy directors place a high premium on shortage suppliers who can move within 48 to 72 hours from request to delivery, with full documentation in order, because in a stock-out the alternative is therapy interruption.

3. Specialty and Orphan Supply

Specialty supply covers product classes where no SFDA-approved locally manufactured equivalent exists. The category includes novel oncology agents, biologic immunotherapies, rare disease enzyme replacement therapies, advanced respiratory biologics, certain ophthalmology biologics, and any product where the global manufacturing footprint has not localised in Saudi Arabia. For these categories, NUPCO and individual hospital procurement continue to source from international suppliers because there is no local alternative to procure from. Specialty supply is the most structurally durable of the three exempt segments because it is anchored not in patient circumstance or supply disruption but in the basic absence of local manufacturing capacity for the product class.

UK exporters serving specialty supply need to be exceptionally precise about regulatory documentation, batch traceability, and cold chain integrity. The major Saudi tertiary centres that drive specialty demand are sophisticated buyers with mature pharmacy departments. Documentation gaps, ambiguity over manufacturer identity, or cold chain excursions are the fastest way to lose a relationship.

Hospital Chains Where Exempt Segments Matter Most

The Saudi hospital landscape includes several institutions whose specialty mandate and clinical case mix means that named patient, shortage, and specialty supply are concentrated there. Understanding which hospitals drive which segments helps UK exporters target their commercial efforts appropriately.

King Faisal Specialist Hospital and Research Centre (KFSH-RC)

KFSH-RC, with its main campus in Riyadh and its Jeddah branch, is the country's flagship tertiary referral centre. It runs internationally accredited programmes in oncology, cardiology, transplantation, and rare disease. The oncology programme alone manages a very substantial proportion of the Kingdom's complex cancer cases, including paediatric oncology and rare adult tumours. The cardiology programme handles complex congenital cases referred from the wider region. The bone marrow transplant and solid organ transplant programmes carry their own demand for specialty immunology and biologic supply. KFSH-RC has historically been a sophisticated international buyer with substantial autonomy in its specialty procurement. Under the 2026 localisation rules, the hospital remains a primary target for UK exporters serving oncology, transplant, rare disease, and advanced biologic supply.

King Fahad Medical City (KFMC)

KFMC is one of Riyadh's largest tertiary medical complexes, providing comprehensive care across most major specialties with particular strengths in cardiology, neurology, oncology, and trauma. The pharmacy department supports clinical trials, named patient cases, and specialty procurement alongside the routine NUPCO framework purchasing. UK exporters with relevant specialty portfolios remain relevant suppliers for the named patient and specialty channels.

King Abdulaziz Medical City (KAMC)

King Abdulaziz Medical City, operated by the Ministry of National Guard Health Affairs, is a flagship of the National Guard medical service with sites in Riyadh, Jeddah, and other regions. It runs significant oncology, cardiology, organ transplant, and specialty clinical programmes. Procurement is integrated with the National Guard medical procurement framework, which itself participates in NUPCO, but specialty and named patient cases continue to draw on international supply where local equivalents do not exist.

King Faisal Specialist Hospital, Jeddah Branch

The KFSH Jeddah branch operates as a parallel tertiary centre to the Riyadh campus, with its own programmes in oncology, paediatric specialty care, and complex surgical care. As with the Riyadh campus, the specialty and named patient channels are where international supply continues to play a central role under the 2026 framework.

Other Specialty Centres

The picture extends beyond the named flagships. The King Saud University Medical City, the Prince Sultan Cardiac Centre network, the Saud Al Babtain Cardiac Centre in the Eastern Province, and several major regional medical centres all run specialty programmes whose pharmaceutical demand profile includes ongoing requirements for international supply in exempt categories. UK exporters working through experienced local agents and group purchasing organisations can map demand systematically across these institutions.

SFDA Registration vs NUPCO Procurement: Two Separate Tracks

One of the most common areas of confusion for UK exporters new to the Saudi market is the relationship between SFDA registration and NUPCO procurement. They are two distinct regulatory and commercial tracks. Conflating them causes wasted effort, misallocated resources, and missed commercial opportunities.

SFDA registration is the marketing authorisation process for routine commercial supply of a pharmaceutical product into the Saudi market. The process involves the appointment of an authorised local agent, the submission of an eCTD dossier covering quality, safety, and efficacy, payment of registration fees, evaluation by the SFDA, and the issuance of a marketing authorisation that permits routine importation, distribution, and sale of the product in Saudi Arabia. SFDA registration is a multi-year commitment in time, cost, and dossier maintenance. It is the precondition for routine commercial supply, including for inclusion in NUPCO framework tenders.

NUPCO procurement is the tendering process by which the public sector buyers actually purchase pharmaceutical products. SFDA registration is necessary but not sufficient for NUPCO procurement. A registered product also has to be tendered, awarded, and called off against the framework agreement. Under the 2026 localisation rules, registration alone does not guarantee tender access in routine categories where SFDA-approved local manufacture exists.

Special Access and named patient supply operates under a third regulatory mechanism distinct from both. The Special Access Program does not require the imported product to hold SFDA marketing authorisation. It requires only a case-by-case approval for a specific identified patient, with the product manufactured to recognised GMP standards and supplied through a licensed local agent. The product enters the Kingdom under a shipment-specific import permit issued by SFDA for the specific case.

The practical implication for UK exporters: investing in full SFDA registration is the right strategy if and only if the product is intended for routine commercial supply in a category where the 2026 localisation rules permit imported finished products to compete in NUPCO tenders. For specialty, rare disease, and orphan products with no realistic local manufacturing equivalent, SFDA registration may still be commercially valuable for predictable hospital procurement. For named patient and shortage supply, SFDA registration is not required at all. The right strategic question is not "should we register?" but "what role do we want to play, and what regulatory pathway serves that role?"

Our companion guide to SFDA drug registration for UK exporters covers the registration pathway in detail.

The Local Manufacturing Landscape in Saudi Arabia

To assess where the 2026 localisation rules bite hardest and where they bite least, UK exporters need a working understanding of the Saudi local manufacturing landscape. The landscape is not uniform across therapeutic areas. Some categories have multiple Saudi manufacturers with established SFDA-approved facilities and broad portfolios. Other categories have effectively no Saudi manufacturing presence at all.

The principal Saudi domestic manufacturers and multinational Saudi-based operations include the following. Each has a defined therapeutic focus, a defined product portfolio, and a defined SFDA registration footprint. UK exporters can use this profile to triangulate which categories are most exposed to localisation pressure and which remain open to imported supply.

• SPIMACO (Saudi Pharmaceutical Industries and Medical Appliances Corporation) is one of the largest domestic manufacturers, with an extensive portfolio across cardiovascular, antimicrobials, gastrointestinal, central nervous system, and over-the-counter categories. Its presence is a significant factor in routine generics localisation.
• Tabuk Pharmaceuticals is a well-established domestic manufacturer with portfolios in cardiovascular, antimicrobials, anti-inflammatories, and various other therapy areas, supplying both local and regional markets.
• Jamjoom Pharma is a Jeddah-based manufacturer with strong presence in dermatology, ophthalmology, paediatrics, and various other categories, supplying both Saudi and wider Middle East markets.
• SAJA Pharmaceuticals covers a portfolio of generic and licensed pharmaceuticals with manufacturing capacity in Riyadh, contributing to the local supply in several therapy areas.
• Riyadh Pharma manufactures a range of pharmaceuticals at its Riyadh facility, covering several major therapy areas with SFDA-approved registration coverage.
• GlaxoSmithKline Saudi Arabia operates a Saudi manufacturing presence as part of GSK's regional strategy, contributing localised manufacture for select branded products in the GSK portfolio.
• Boehringer Ingelheim Saudi Arabia similarly maintains a localised manufacturing and commercial presence supporting Boehringer's regional supply.

The collective effect of this landscape is that routine therapeutic categories, common cardiovascular drugs, broad-spectrum antibiotics, common analgesics, oral antidiabetics, frequently prescribed psychotropics, are well covered by SFDA-approved Saudi-manufactured options. Categories that remain thinly covered or uncovered locally include novel oncology agents, advanced biologic immunotherapies, rare disease enzyme replacements, advanced respiratory biologics, ophthalmology biologics, and various specialty haematology products. UK exporters whose portfolios sit in the latter set are the natural fit for ongoing Saudi supply under the 2026 framework.

Implications by Therapeutic Area

The 2026 localisation rules do not affect every therapeutic area equally. UK exporters should map their portfolios against the local manufacturing landscape and adjust their commercial focus accordingly.

Oncology

Oncology is, in many respects, the cleanest illustration of where UK supply remains essential. Routine cytotoxic and supportive care products are increasingly available from local manufacture, but novel oncology agents, including targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, and CAR-T related supply, are concentrated in international manufacturing. KFSH-RC's oncology programme, KFMC's oncology services, and KAMC oncology services continue to demand specialty supply that local manufacture cannot replace. UK exporters with oncology portfolios in our oncology category remain highly relevant.

Cardiovascular

Cardiovascular is largely localised. Standard ACE inhibitors, ARBs, beta blockers, calcium channel blockers, statins, and routine antiplatelets are well covered by Saudi manufacture. UK supply in cardiovascular concentrates on novel agents, complex injectable cardiac drugs, specialty pulmonary hypertension therapies, and named patient cases for non-routine cardiac indications. Routine generic cardiovascular tendering through NUPCO is the segment most directly affected by the 2026 rules.

Antibiotics and Antimicrobials

Standard broad-spectrum antibiotics are heavily localised. UK supply role concentrates on second-line antifungals for invasive infection in immunocompromised patients, specialty antiparasitic and antiviral therapies, and shortage supply when local manufacture interrupts. Specialty antimicrobials remain accessible through exempt channels.

Biologics and Immunotherapies

Biologics, including monoclonal antibodies, immunomodulators, and biologic enzyme therapies, are predominantly manufactured outside the Kingdom. UK supply remains structurally relevant for biologic categories across rheumatology, gastroenterology, dermatology, oncology, and rare disease. Named patient and specialty supply is the dominant route.

Insulins and Diabetes Therapies

Insulin supply is partially localised through licensed local manufacturing partnerships, but novel diabetes therapies, including newer GLP-1 receptor agonists, dual incretin agents, and specialty injectables, remain primarily international. UK supply continues to support specialty diabetes and endocrinology cases through named patient and shortage channels.

Vaccines

Vaccines are largely procured by the Ministry of Health and the Public Health Authority through a separate central procurement channel that operates outside the routine NUPCO framework. The Public Health Authority leads on the national immunisation programme and on outbreak response. Specialty vaccines for travel medicine, individual patient indications, and rare disease prophylaxis continue to be sourced through named patient and Special Access pathways.

Rare Disease and Orphan Therapies

Rare disease therapy is, structurally, the most internationally dependent category in the Saudi market and likely to remain so. Enzyme replacement therapies for lysosomal storage disorders, advanced therapies for haematological rare diseases, specialty neurology therapies for genetic disorders, and orphan oncology agents are almost entirely sourced through named patient and Special Access pathways. UK supply concentrates here.

Compliance Requirements That Have Not Changed

One important point. The 2026 localisation rules change the procurement preference framework. They do not relax any of the compliance, quality, or documentation standards for international supply. Anything that was required from a UK supplier before the 2026 rules is still required, and in some respects, the documentation expectations have tightened as Saudi authorities have aligned more closely with international best practice.

The expected documentation package for UK supply into Saudi Arabia under any of the exempt pathways continues to include the following:

The principle is straightforward: localisation policy changes who is preferred. Compliance and quality standards remain non-negotiable for any product entering the Kingdom regardless of localisation status. UK exporters with mature GDP and MHRA compliance infrastructure are well placed to meet these standards.

NUPCO Bidding Mechanics in Brief

For UK exporters whose portfolios fall outside the localisation pressure points and who do intend to participate in routine NUPCO tenders, the bidding mechanics are worth understanding. NUPCO operates an electronic tendering portal through which suppliers, working in partnership with their authorised local agents, register, qualify, respond to tender publications, and submit bids. The tendering process can include framework agreements, mini-competitions within frameworks, and ad-hoc tenders for specific clinical needs.

Eligibility documentation typically required includes the local agent's commercial registration and Drug Sector import licence, the foreign supplier's MHRA WDA evidence, the product's SFDA marketing authorisation certificate, manufacturing GMP certificates, a Certificate of Pharmaceutical Product, sample certificate of analysis, and pricing supported by reference pricing documentation. Tender evaluation increasingly weighs local content alongside price and quality, in line with the 2026 localisation policy.

UK exporters new to NUPCO should expect that the operational tempo, documentation expectations, and competitive landscape are demanding. Working with an experienced authorised local agent who understands the NUPCO portal, the typical tender cadence in the relevant therapy area, and the relationships at the major hospital pharmacy departments is a precondition for a serious tender effort. UK suppliers can supplement this with strong UK-side documentation, fast tender response turnaround, and clear evidence of GDP compliance, but the local agent partnership is the foundation.

The Named Patient Pathway in Saudi Arabia: Working Mechanics

Because the named patient pathway is one of the three exempt segments and because it is the segment where UK MHRA-licensed wholesalers are arguably most relevant under the 2026 framework, it deserves a more detailed working description than the simpler procurement channels.

A named patient case in Saudi Arabia typically progresses as follows:

1. Clinical identification. A clinician at a Saudi hospital identifies a patient who requires a specific medicine that is not registered in Saudi Arabia or is registered but not available, and who cannot be adequately treated by any locally available alternative.
2. Hospital review. The case is reviewed by the hospital's pharmacy and therapeutics committee, by a Special Use Committee, or by an equivalent body depending on the institution. The reviewer evaluates the clinical justification, considers alternatives, and approves the case for special access procurement.
3. SFDA application. A Special Access Program application is submitted to the SFDA, supported by clinical justification, product details, manufacturer details, and supplier details. The application typically identifies a specific patient case, sometimes coded for confidentiality, with clinical rationale.
4. Approval and import permit. Once approved, the SFDA issues a shipment-specific import permit. The permit references the patient case, specifies the approved quantity, and authorises importation through the licensed local agent.
5. UK supplier engagement. The local agent contacts the UK supplier with the product specification, the required quantity, the documentation requirements, and the timeline. The UK MHRA-licensed wholesaler sources the product, prepares documentation, and arranges shipment.
6. Cold chain and air freight. For temperature-sensitive products, the wholesaler validates the shipping configuration, attaches data loggers, and dispatches via Heathrow with direct air freight to the destination airport.
7. Customs clearance. The local agent presents the import permit and supporting documentation to Saudi customs at the destination airport, clears the consignment, and arranges onward delivery to the hospital.
8. Hospital receipt. The hospital pharmacy receives the consignment, verifies documentation and cold chain integrity, and dispenses the medicine to the identified patient.

Timelines vary. Urgent named patient cases for life-threatening conditions can be processed in 5 to 10 working days from clinical identification to hospital receipt, with the rate-limiting step often being SFDA approval rather than UK-side preparation. Standard named patient cases may take 14 to 21 working days. The UK supplier's role is to be reliable, fast, fully documented, and capable of cold chain integrity. UK exporters who fail any of these tests do not survive long in the Saudi named patient channel.

Strategic Positioning for UK Exporters Post-2026

Pulling the threads together, what is the right strategic posture for a UK pharmaceutical exporter looking at Saudi Arabia in 2026 and beyond?

The first principle is segmentation. The Saudi market is not a single market. It is at least four markets sitting under one regulatory umbrella: routine NUPCO procurement of localised categories, NUPCO procurement of categories without local manufacture, named patient and Special Access supply, and shortage and emergency supply. Each market has different rules, different timelines, different commercial dynamics, and different strategic implications. UK exporters who treat them as one will get the strategy wrong.

The second principle is portfolio fit. UK exporters with portfolios concentrated in routine generics where Saudi local manufacture is well established should expect a structural decline in their NUPCO tender win rates and either reposition the portfolio toward exempt categories or accept a smaller Saudi footprint. UK exporters with portfolios in specialty oncology, biologics, rare disease, advanced respiratory, and other categories with limited local manufacture should view the 2026 framework as a clarifying rather than constraining force, with their differentiated value proposition becoming more visible.

The third principle is operational excellence in the exempt segments. Named patient supply, shortage supply, and specialty supply all reward the same operational characteristics: rigorous documentation, fast turnaround, GDP-compliant cold chain integrity, robust manufacturer relationships, deep regulatory expertise. UK exporters who invest in these capabilities differentiate themselves from competitors who treat exempt-channel supply as a side activity rather than a core capability.

The fourth principle is partnership with sophisticated local agents. The 2026 framework rewards UK exporters who work with local agents that have deep relationships at the major tertiary hospitals, that understand the SFDA Special Access process intimately, that move quickly on named patient cases, and that maintain disciplined commercial conduct in the post-localisation environment. The local agent landscape in Saudi Arabia varies in quality. UK exporters should be selective about partnership.

The fifth principle is realism about the broader Gulf trajectory. As we note in our GCC pharmaceutical export guide, localisation policy is a Gulf-wide trend, not a Saudi-only trend. The UAE, Qatar, Kuwait, Bahrain, and Oman all operate national vision strategies with healthcare manufacturing localisation as an objective. The pace and depth of implementation differs, but UK exporters should expect a gradual broader directional shift across the Gulf and structure their commercial strategy accordingly.

How Euro Biom Supports UK to Saudi Supply Post-2026

Euro Biom is a UK MHRA-licensed Wholesale Dealer Authorisation holder, WDA(H) 59239, operating from a Heathrow base with direct access to the Saudi air freight corridor. Our positioning under the 2026 framework is deliberate. We are not a generic commodity supplier competing for routine NUPCO tenders against locally manufactured products. We are a specialty, named patient, and shortage supply partner working with Saudi hospital pharmacy teams, local agents, and group purchasing organisations to ensure that patients who need medicines from outside the Kingdom continue to receive them.

Our service mix includes:

• Named patient supply for individual identified patient cases, with full Special Access Program documentation support and rapid turnaround. See our dedicated named patient supply service page.
• Urgent shortage supply when local manufacture interrupts or stocks out, with same-day Heathrow dispatch and 48 to 72 hour delivery to Saudi airports.
• Specialty product sourcing in oncology, biologics, rare disease, and other categories where SFDA-approved local equivalents do not exist.
• Cold chain integrity for temperature-sensitive products, with validated 2 to 8 degrees Celsius transport configurations and continuous data logging. Our companion cold chain supply to Saudi Arabia page covers the technical detail.
• Full documentation packages for every shipment, including Certificate of Pharmaceutical Product, certificate of analysis, batch release documentation, GDP-compliant packing list, and Arabic labelling support where required.
• Reference Listed Drug supply for Saudi clinical research and bioequivalence studies. Our reference listed drug supply service supports CDER-aligned and EMA-aligned RLD sourcing.
• Managed Access Programme support for early access and compassionate use cases through our managed access programmes service.
• Specials and unlicensed medicine sourcing through our specials and unlicensed medicines service for Saudi cases requiring non-routine product forms.
• Tender and government supply support for Saudi institutional buyers operating outside the routine NUPCO localisation framework, through our tender and government supply service.

For UK manufacturers and exporters who want to discuss how the 2026 framework affects their specific portfolio and how Euro Biom can support their Saudi commercial strategy, we are reachable through our standard enquiry channel or directly at work@eurobiom.co.uk. For Saudi hospital pharmacy teams and local agents seeking a UK supplier with the operational capability to support named patient, shortage, and specialty supply post-2026, the same channels apply. Our companion guide on how to import medicines from the UK into Saudi Arabia and the UAE covers the wider operational picture across the Gulf.

The 2026 framework is, in our reading, a clarifying moment rather than a closing one. The UK pharmaceutical export community can either treat it as a defensive challenge or as an opportunity to sharpen its specialty positioning. We are firmly in the second camp, and we expect the next several years to make that posture look more right rather than less. We see continuing demand from KFSH-RC oncology, from KFMC neurology and oncology, from KAMC specialty programmes, from rare disease practitioners across the Kingdom, and from hospital pharmacy directors managing the daily reality of stock-outs and named patient requests. UK supply, MHRA quality, and Heathrow speed are part of the answer to those daily realities. The 2026 rules do not change that. They make it clearer.

For deeper operational and regulatory context, our additional services overview outlines the full Euro Biom capability set, and our compliance page documents our GDP and MHRA quality framework in full.